Estimates of the global burden of non-Hodgkin lymphoma attributable to HIV: a population attributable modeling study

[1]  J. Ruokolainen,et al.  Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities , 2023, Molecular pharmaceutics.

[2]  C. Correll,et al.  Impact of mental disorders on clinical outcomes of physical diseases: an umbrella review assessing population attributable fraction and generalized impact fraction , 2023, World psychiatry : official journal of the World Psychiatric Association.

[3]  M. Egger,et al.  Age and cancer incidence in 5.2 million people with HIV: the South African HIV Cancer Match study. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Biruk Bayleyegn,et al.  HIV/AIDS Associated Lymphoma: Review , 2022, Blood and lymphatic cancer : targets and therapy.

[5]  C. de Martel,et al.  Epstein‐Barr virus prevalence among subtypes of malignant lymphoma in Rwanda, 2012 to 2018 , 2021, International journal of cancer.

[6]  M. Mansournia,et al.  Population attributable fraction in textbooks: Time to revise , 2021, Global epidemiology.

[7]  Luoping Zhang,et al.  Benzene exposure and non-Hodgkin lymphoma: a systematic review and meta-analysis of human studies , 2021, The Lancet. Planetary health.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  F. Bray,et al.  Estimates of the global burden of cervical cancer associated with HIV , 2020, The Lancet. Global health.

[10]  Ravensara S. Travillian,et al.  Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[11]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[12]  M. Mansournia,et al.  Estimation of Generalized Impact Fraction and Population Attributable Fraction of Hypertension Based on JNC-IV and 2017 ACC/AHA Guidelines for Cardiovascular Diseases Using Parametric G-Formula: Tehran Lipid and Glucose Study (TLGS) , 2020, Risk management and healthcare policy.

[13]  Yu Wang,et al.  Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2+ T cells activities after hematopoietic transplantation for blood malignancies , 2020, Journal for ImmunoTherapy of Cancer.

[14]  M. Mansournia,et al.  Methods matter: population attributable fraction (PAF) in sport and exercise medicine , 2020, British Journal of Sports Medicine.

[15]  K. Looker,et al.  Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data , 2019, The Lancet. Infectious diseases.

[16]  E. Kobetz,et al.  Epidemiology and Etiology of Leukemia and Lymphoma. , 2019, Cold Spring Harbor perspectives in medicine.

[17]  A. Ogunniyi,et al.  Rapid HIV Antigen-Antibody Assays and Detection of Acute HIV Infection in Sub-Saharan Africa. , 2019, The American journal of tropical medicine and hygiene.

[18]  P. Sullivan,et al.  Progress in the HIV epidemic: Identifying goals and measuring success , 2019, PLoS medicine.

[19]  S. Rajagopalan,et al.  Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis , 2018, Circulation.

[20]  M. Dybul,et al.  Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission , 2018, The Lancet.

[21]  P. Rosenberg,et al.  Projected Cancer Incidence Rates and Burden of Incident Cancer Cases in HIV-Infected Adults in the United States Through 2030 , 2018, Annals of Internal Medicine.

[22]  E. Engels,et al.  Spectrum of cancer risk among HIV-infected people in the United States during the modern antiretroviral therapy era: a population-based registry linkage study , 2017, The lancet. HIV.

[23]  C. Hoffmann,et al.  HIV-Associated Malignant Lymphoma , 2017, Oncology Research and Treatment.

[24]  J. Castillo,et al.  Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy , 2016, AIDS.

[25]  T. Friede,et al.  Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies , 2015, BMC Medical Research Methodology.

[26]  Jennifer Kelly,et al.  Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes Project. , 2014, Journal of the National Cancer Institute. Monographs.

[27]  George F Borm,et al.  The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method , 2014, BMC Medical Research Methodology.

[28]  Randy D Gascoyne,et al.  Non-Hodgkin lymphoma , 2016, Medicine.

[29]  B. Nathwani,et al.  Epstein–Barr virus patterns in US Burkitt lymphoma tumors from the SEER residual tissue repository during 1979–2009 , 2014, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[30]  A. Siika,et al.  Hepatitis C virus (HCV) infection in Africa: a review , 2013, The Pan African medical journal.

[31]  Kate R Shankland,et al.  Non-Hodgkin lymphoma , 2012, The Lancet.

[32]  D. Parkin.  11. Cancers attributable to infection in the UK in 2010 , 2011, British Journal of Cancer.

[33]  H. Varmus,et al.  Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention , 2011, Science Translational Medicine.

[34]  J. Kutok,et al.  Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. , 2010, Cancer cell.

[35]  X. Sagaert,et al.  Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development , 2010, Nature Reviews Gastroenterology &Hepatology.

[36]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[37]  O. Martínez-Maza,et al.  Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions , 2006, Current opinion in oncology.

[38]  J. Goedert,et al.  Trends in cancer risk among people with AIDS in the United States 1980–2002 , 2006, AIDS.

[39]  P. Bieniasz.  Intrinsic immunity: a front-line defense against viral attack , 2004, Nature Immunology.

[40]  D. Weisenburger,et al.  An update of the epidemiology of non-Hodgkin's lymphoma. , 2003, Clinical lymphoma.

[41]  R. Koup,et al.  T cell dynamics in HIV-1 infection. , 2003, Annual review of immunology.

[42]  P. Foster,et al.  The viral manipulation of the host cellular and immune environments to enhance propagation and survival: a focus on RNA viruses , 2002, Journal of leukocyte biology.

[43]  D. Knowles.  Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. , 1996, Hematology/oncology clinics of North America.

[44]  D. Federman,et al.  The epidemiology of non-Hodgkin's lymphoma. , 1996, Connecticut medicine.

[45]  P. Hartge,et al.  Role of HTLV-I in development of non-Hodgkin lymphoma in Jamaica and Trinidad and Tobago , 1993, The Lancet.

[46]  G. Inghirami,et al.  Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. , 1988, Blood.

[47]  P. Pelicci,et al.  Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis , 1986, The Journal of experimental medicine.

[48]  Á. Borges.  Combination antiretroviral therapy and cancer risk , 2017, Current opinion in HIV and AIDS.

[49]  E. Feuer,et al.  Partitioning linear trends in age-adjusted rates , 2004, Cancer Causes & Control.

[50]  R. Mertelsmann,et al.  Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology , 2004, Annals of Hematology.

[51]  C. van den Bosch,et al.  Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter? , 2004, The Lancet. Oncology.

[52]  G. Gaidano,et al.  Molecular pathogenesis of AIDS-related lymphomas. , 1994, Antibiotics and chemotherapy.

[53]  J. Sparano,et al.  Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: a highly active regimen. , 1993, Blood.

[54]  PhD No. Zhengwei Wan,et al.  CLINICAL AND POPULATION SCIENCES Global and Regional Estimate of HIV-Associated Stroke Burden : A Meta-Analysis and Population Attributable Modeling Study , 2022 .